Latest From Cytokinetics Inc.
Scrip spoke with R&D head David Reese about improving R&D timelines and success rates, including through the use of genomics and proteomics, as data readouts near for key drugs in big indications.
The introductions of Spinraza and Zolgensma in SMA offer new insights into how to address neurodegenerative diseases. But more real world evidence is needed.
Public Company Edition: Five biopharma firms went public in the US in recent weeks, but Inhibrx withdrew its IPO and Monopar postponed its offering. Also, Tot Biopharm launched an IPO in Hong Kong, while Epizyme sold royalties and issued debt to raise up to $270m.
Roche's main consideration when partnering is to "access great science" regardless of location. More of this is expected to come out of Asia, its global partnering head tells Scrip.
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Cytokinetics Inc.
- Senior Management
Robert I Blum, Pres. & CEO
Ching W Jaw, SVP, CFO
Andrew A Wolff, MD, SVP, CMO
Elisabeth A Schnieders, PhD, SVP, Bus. Dev.
Scott R Jordan, SVP, Commercial Dev.
- Contact Info
Phone: (650) 624-3000
280 East Grand Ave.
S. San Francisco, CA 94080
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.